Remy
Administrator
This article seems very applicable to MECFS as well as to CVID (a serious form of immune deficiency where the B cells needed to fight infections are absent or markedly reduced). But the benefits of IVIG seem to go beyond just mere replacement of missing antibodies and extend into immune modulating territory as well. This would likely have benefits for MECFS as well even though the results of trials have been mixed thus far.
With the advent of subQ IgG replacement (Hizentra), it would seem that IVIG should be in reach for a lot more patients in our cohort. I think getting IgG levels (both total and subclasses) is a very important laboratory test that seems to be mostly overlooked in our population.
With the advent of subQ IgG replacement (Hizentra), it would seem that IVIG should be in reach for a lot more patients in our cohort. I think getting IgG levels (both total and subclasses) is a very important laboratory test that seems to be mostly overlooked in our population.
In the case of CVID, IVIg has mainly been seen as reconstitution therapy, providing patients with pathogen-specific antibodies. Recent evidence shows that IVIg has diverse effects on the immune system of CVID patients, and one important component is that IVIg alleviates the state of chronic immune activation. In this review, we will discuss causes and consequences of persistent immune activation in CVID, possible underlying mechanisms for how IVIg treatment reduces immune activation, and implications for our understanding of primary as well as acquired immune deficiencies.